Groups
Company Type
Sector
Conference attendance
Index
Reset

Hans-Peter Ekre Sweden

Bactaviva offers novel services for prevention of disturbed gut flora through safe and convenient personalized fecal microbiota transplantation with capsules, and cutting edge microbiota analysis.

The Problem

Medical procedures that compromise the immune defense carries a risk for opportunistic pathogens in the GI tract. With personalized fecal microbiota transplantation, using healthy autologus fecal microbiota, right after the completed medical procedure, this risk is markedly reduced.

The most pronounced medical need is recurrent Clostridium difficile infections (CDI). After broadspectrum antibiotics treatment about 25% get recurrent disease. Hospitalization is common with annual costs in acute-care facilities in the U.S. of 4.8 BUSD, and a mortality from recurrent CDI of 29,000 /year.

Fecal microbiota transplantation, FMT, has shown excellent treatment effects, but is expensive, cumbersome and inconvenient, not regulated by authorities and has a risk for transmission of infections and antibiotic resistant bacteria from donors.

 

Our solution

The Bactaviva personalized FMT allows immediate implementation to prevent and treat microbiota dysbiosis cuased by antibiotics, traveller’s infections and to prevent resistant strains to establish. It is safe, cost-effective and very convenient for patients and health providers. The Bactaviva library of healthy 16S rRNA and DNA microbiomes will be a unique source of information.

Development stage

A process for collection, analysis, storage and encapsulation has been established. A patent application was filed in January 2017.

 

With a grant from EIT Health a controlled clinical intervention study is planned for the next 6 months in volunteers comparing safety, and also microbiota recovery, after an antibiotics regimen.

We look for

Industrial investor(s) who can invest 2.5 + 2.5 M€ to establish laboratories, launch the services and actively contribute to internationalization.

Added values to sales will be the company’s market presence, KOL network and unique microbiome library; a good base for development and partnering.

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Sector
The Bactaviva Project
Project leader (CEO) and co-founder 
Conference attendance
BEF

Janine Erler

Website:
https://erlerlab.com/
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Website
https://erlerlab.com/
Company Profile

1 in 3 people will develop cancer during their lifetime, and over 90% of cancer patient deaths are caused when the cancer spreads though the body, a process called metastasis. We have identified an excellent anti-metastatic target for therapy development. Extensive pre-clinical models have shown therapeutic efficacy of targeting an enzyme called Lysyl oxidase (LOX). In addition, LOX expression is clinically correlated with metastasis and poor survival in cancer patients. Moreover, LOX is implicated in fibrosis and initial pre-clinical studies suggest LOX may also be an effective therapeutic target for limiting fibrosis. We are currently developing new antibodies against LOX that we are testing pre-clinically with the intention to move into clinical trials in human patients. Our work thus has great potential to develop new effective therapies of commercial value, and offers a real potential to impact on patient well being and survival.

The Erler Laboratory
Professor in cancer biology 
Conference attendance
BEF